Human in vivo research on the vascular effects of adenosine

European Journal of Pharmacology

Volumn 585, Issue 2-3, 2008, Pages 220-227

  Riksen, Niels P ^a,b   Rongen, Gerard A ^a   Yellon, Derek ^b   Smits, Paul ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adenosine; Annexin A5 scintigraphy; Forearm blood flow; Human in vivo; Ischaemia reperfusion injury; Plethysmography; Polymorphism

Indexed keywords

ADENOSINE; ADENOSINE PHOSPHATE; ADENOSINE RECEPTOR; CAFFEINE; DIPYRIDAMOLE; DRAFLAZINE; HOMOCYSTEINE; LIPOCORTIN 5; LOSARTAN; METHOTREXATE; REGADENOSON; TECHNETIUM 99M; THEOPHYLLINE;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CEREBROVASCULAR DISEASE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EFFECT; DRUG HALF LIFE; DRUG INHIBITION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TRANSPORT; GENETIC VARIABILITY; HEART HEMODYNAMICS; HEART INFARCTION; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RHEUMATOID ARTHRITIS; SCINTIGRAPHY; SINGLE NUCLEOTIDE POLYMORPHISM; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ADENOSINE; BLOOD VESSELS; HUMANS;

EID: 43049095683     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.01.053     Document Type: Review

References (93)

1. 2A receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 28 (2003) 1694-1702
2. Anderson J.L., Habashi J., Carlquist J.F., Muhlestein J.B., Horne B.D., Bair T.L., Pearson R.R., and Hart N. A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J. Am. Coll. Cardiol. 36 (2000) 1248-1252
3. Belardinelli L., Linden J., and Berne R.M. The cardiac effects of adenosine. Prog. Cardiovasc. Dis. 32 (1989) 73-97
4. 2A adenosine receptor mediates coronary vasodilation. J. Pharmacol. Exp. Ther. 284 (1998) 1066-1073
5. Benjamin N., Calver A., Collier J., Robinson B., Vallance P., and Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 25 (1995) 918-923
6. Biaggioni I., Onrot J., Hollister A.S., and Robertson D. Cardiovascular effects of adenosine infusion in man and their modulation by dipyridamole. Life Sci. 39 (1986) 2229-2236
7. Biaggioni I., Olafsson B., Robertson R.M., Hollister A.S., and Robertson D. Cardiovascular and respiratory effects of adenosine in conscious man. Evidence for chemoreceptor activation. Circ. Res. 61 (1987) 779-786
8. Bijlstra P., van Ginneken E.E., Huls M., Van Dijk R., Smits P., and Rongen G.A. Glyburide inhibits dipyridamole-induced forearm vasodilation but not adenosine-induced forearm vasodilation. Clin. Pharmacol. Ther. 75 (2004) 147-156
9. Bonaa K.H., Njolstad I., Ueland P.M., Schirmer H., Tverdal A., Steigen T., Wang H., Nordrehaug J.E., Arnesen E., and Rasmussen K. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med. 354 (2006) 1578-1588
10. 3 receptors in protection of isolated human atrial muscle against simulated ischaemia. Cardiovasc. Res. 36 (1997) 52-59
11. Chen Y.F., Li P.L., and Zou A.P. Effect of hyperhomocysteinemia on plasma or tissue adenosine levels and renal function. Circulation 106 (2002) 1275-1281
12. Conradson T.B., Dixon C.M., Clarke B., and Barnes P.J. Cardiovascular effects of infused adenosine in man: potentiation by dipyridamole. Acta Physiol. Scand. 129 (1987) 387-391
13. Cornelis M.C., El-Sohemy A., Kabagambe E.K., and Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 295 (2006) 1135-1141
14. Costa F., and Biaggioni I. Role of adenosine in the sympathetic activation produced by isometric exercise in humans. J. Clin. Invest. 93 (1994) 1654-1660
15. Costa F., and Biaggioni I. Role of nitric oxide in adenosine-induced vasodilation in humans. Hypertension 31 (1998) 1061-1064
16. Cox D.A., Vita J.A., Treasure C.B., Fish R.D., Selwyn A.P., and Ganz P. Reflex increase in blood pressure during the intracoronary administration of adenosine in man. J. Clin. Invest. 84 (1989) 592-596
17. Deussen A., Stappert M., Schafer S., and Kelm M. Quantification of extracellular and intracellular adenosine production: understanding the transmembranous concentration gradient. Circulation 99 (1999) 2041-2047
18. Deussen A. Metabolic flux rates of adenosine in the heart. Naunyn-Schmiedeberg's Arch. Pharmacol. 362 (2000) 351-363
19. Drury A.N., and Szent-Gyorgyi A. The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. J. Physiol. 68 (1929) 213-237
20. Figueredo V.M., Diamond I., Zhou H.Z., and Camacho S.A. Chronic dipyridamole therapy produces sustained protection against cardiac ischemia-reperfusion injury. Am. J. Physiol. 277 (1999) H2091-H2097
21. FitzGerald G.A. Dipyridamole. N. Engl. J. Med. 316 (1987) 1247-1257
22. Forrest C.M., Stoy N., Stone T.W., Harman G., Mackay G.M., Oxford L., and Darlington L.G. Adenosine and cytokine levels following treatment of rheumatoid arthritis with dipyridamole. Rheumatol. Int. 27 (2006) 11-17
23. Fredholm B.B., Battig K., Holmen J., Nehlig A., and Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51 (1999) 83-133
24. Fredholm B.B., IJzerman A.P., Jacobson K.A., Klotz K.N., and Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53 (2001) 527-552
25. Gamboa A., Ertl A.C., Costa F., Farley G., Manier M.L., Hachey D.L., Diedrich A., and Biaggioni I. Blockade of nucleoside transport is required for delivery of intraarterial adenosine into the interstitium: relevance to therapeutic preconditioning in humans. Circulation 108 (2003) 2631-2635
26. Gamboa A., Abraham R., Diedrich A., Shibao C., Paranjape S.Y., Farley G., and Biaggioni I. Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole. Stroke 36 (2005) 2170-2175
27. Gorlach A. Control of adenosine transport by hypoxia. Circ. Res. 97 (2005) 1-3
28. Goto M., Miura T., Iliodoromitis E.K., O'Leary E.L., Ishimoto R., Yellon D.M., and Iimura O. Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species. Cardiovasc. Res. 25 (1991) 943-949
29. Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., and Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367 (2006) 1665-1673
30. Hammill A.K., Uhr J.W., and Scheuermann R.H. Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Exp. Cell Res. 251 (1999) 16-21
31. Hand B.D., Roth S.M., Roltsch M.H., Park J.J., Kostek M.C., Ferrell R.E., and Brown M.D. AMPD1 gene polymorphism and the vasodilatory response to ischemia. Life Sci. 79 (2006) 1413-1418
32. Headrick J.P., Hack B., and Ashton K.J. Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am. J. Physiol., Heart Circ. Physiol. 285 (2003) H1797-H1818
33. Kalsi K.K., Yuen A.H., Rybakowska I.M., Johnson P.H., Slominska E., Birks E.J., Kaletha K., Yacoub M.H., and Smolenski R.T. Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation - a potential mechanism of protection in heart failure. Cardiovasc. Res. 59 (2003) 678-684
34. 2B receptors. Br. J. Pharmacol. 126 (1999) 1796-1800
35. Kin H., Zatta A.J., Lofye M.T., Amerson B.S., Halkos M.E., Kerendi F., Zhao Z.Q., Guyton R.A., Headrick J.P., and Vinten-Johansen J. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc. Res. 67 (2005) 124-133
36. Lasley R.D., Hegge J.O., Noble M.A., and Mentzer R.M. Evidence that cytosolic and ecto 5 ′-nucleotidases contribute equally to increased interstitial adenosine concentration during porcine myocardial ischemia. Basic Res. Cardiol. 94 (1999) 199-207
37. 2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J. Nucl. Cardiol. 14 (2007) 514-520
38. Linden J. Adenosine in tissue protection and tissue regeneration. Mol. Pharmacol. 67 (2005) 1385-1387
39. 1 adenosine receptors in rabbit heart. Circulation 84 (1991) 350-356
40. Loh E., Rebbeck T.R., Mahoney P.D., DeNofrio D., Swain J.L., and Holmes E.W. Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation 99 (1999) 1422-1425
41. Lonn E., Yusuf S., Arnold M.J., Sheridan P., Pogue J., Micks M., McQueen M.J., Probstfield J., Fodor G., Held C., and Genest Jr. J. Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med. 354 (2006) 1567-1577
42. Martin E.A., Nicholson W.T., Eisenach J.H., Charkoudian N., and Joyner M.J. Bimodal distribution of vasodilator responsiveness to adenosine due to difference in nitric oxide contribution: implications for exercise hyperemia. J. Appl. Physiol 101 (2006) 492-499
43. Martin E.A., Nicholson W.T., Eisenach J.H., Charkoudian N., and Joyner M.J. Influences of adenosine receptor antagonism on vasodilator responses to adenosine and exercise in adenosine responders and nonresponders. J. Appl. Physiol 101 (2006) 1678-1684
44. Martin E.A., Nicholson W.T., Curry T.B., Eisenach J.H., Charkoudian N., and Joyner M.J. Adenosine transporter antagonism in humans augments vasodilator responsiveness to adenosine, but not exercise, in both adenosine responders and non-responders. J. Physiol 579 (2007) 237-245
45. McCann W.P., and Katholi R.E. Control of artifacts in plasma adenosine determinations. Proc. Soc. Exp. Biol. Med. 194 (1990) 314-319
46. 2A receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 791-796
47. 3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum. 48 (2003) 240-247
48. Montesinos M.C., Takedachi M., Thompson L.F., Wilder T.F., Fernandez P., and Cronstein B.N. The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5 ′-nucleotidase: findings in a study of ecto-5 ′-nucleotidase gene-deficient mice. Arthritis Rheum. 56 (2007) 1440-1445
49. Morisaki T., Gross M., Morisaki H., Pongratz D., Zollner N., and Holmes E.W. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 6457-6461
50. Moser G.H., Schrader J., and Deussen A. Turnover of adenosine in plasma of human and dog blood. Am. J. Physiol 256 (1989) C799-C806
51. Muller M. Science, medicine, and the future: Microdialysis. BMJ 324 (2002) 588-591
52. Murry C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986) 1124-1136
53. Nees S., Herzog V., Becker B.F., Bock M., Des R.C., and Gerlach E. The coronary endothelium: a highly active metabolic barrier for adenosine. Basic Res. Cardiol. 80 (1985) 515-529
54. Newby A.C. Adenosine and the concept of retaliatory metabolites. Trends Biochem. Sci. 9 (1984) 42-44
55. Olafsson B., Forman M.B., Puett D.W., Pou A., Cates C.U., Friesinger G.C., and Virmani R. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 76 (1987) 1135-1145
56. Peart J.N., and Headrick J.P. Adenosinergic cardioprotection: multiple receptors, multiple pathways. Pharmacol. Ther. 114 (2007) 208-221
57. Riksen N.P., Rongen G.A., Blom H.J., Russel F.G.M., Boers G.H.J., and Smits P. Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia. Cardiovasc. Res. 59 (2003) 271-276
58. Riksen N.P., Barrera P., Van den Broek P.H., van Riel P., Smits P., and Rongen G. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann. Rheum. Dis. 65 (2005) 465-470
59. Riksen N.P., van Ginneken E.E., Van den Broek P.H., Smits P., and Rongen G.A. In vivo evidence against a role for adenosine in the exercise pressor reflex in humans. J. Appl. Physiol 99 (2005) 522-527
60. Riksen N.P., Oyen W.J., Ramakers B.P., Van den Broek P.H., Engbersen R., Boerman O.C., Smits P., and Rongen G.A. Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clin. Pharmacol. Ther. 78 (2005) 52-59
61. Riksen N.P., Rongen G.A., Blom H.J., Boers G.H., and Smits P. Reduced adenosine receptor stimulation as a pathogenic factor in hyperhomocysteinemia. Clin. Chem. Lab Med. 43 (2005) 1001-1006
62. Riksen N.P., Rongen G.A., Boers G.H.J., Blom H.J., van den Broek P.H.H., and Smits P. Enhanced cellular adenosine uptake limits adenosine receptor stimulation in patients with hyperhomocysteinemia. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 109-114
63. Riksen N.P., Zhou Z., Oyen W.J., Jaspers R., Ramakers B.P., Brouwer R.M., Boerman O.C., Steinmetz N., Smits P., and Rongen G.A. Caffeine prevents protection in two human models of ischemic preconditioning. J. Am. Coll. Cardiol. 48 (2006) 700-707
64. 2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo. Pharmacogenet. Genomics 17 (2007) 551-554
65. Riksen N.P., Franke B., Oyen W.J., Borm G.F., van den Broek P., Boerman O.C., Smits P., and Rongen G.A. Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C>T variant of the AMPD1 gene. Eur. Heart J. 28 (2007) 1085-1091
66. Rongen G.A., Smits P., Verdonck D.K., Willemsen J.J., De Abreu R.A., Van Belle H., and Thien T. Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection. J. Clin. Invest. 95 (1995) 658-668
67. Rongen G.A., Lenders J.W., Lambrou J., Willemsen J.J., Van Belle H., Thien T., and Smits P. Presynaptic inhibition of norepinephrine release from sympathetic nerve endings by endogenous adenosine. Hypertension 27 (1996) 933-938
68. Rongen G.A., Floras J.S., Lenders J.W., Thien T., and Smits P. Cardiovascular pharmacology of purines. Clin. Sci. 92 (1997) 13-24
69. Rongen G.A., Brooks S.C., Ando S., Abramson B.L., and Floras J.S. Angiotensin AT1 receptor blockade abolishes the reflex sympatho-excitatory response to adenosine. J. Clin. Invest. 101 (1998) 769-776
70. Rongen G.A., Brooks S.C., Ando S., Notarius C.F., and Floras J.S. Caffeine abstinence augments the systolic blood pressure response to adenosine in humans. Am. J. Cardiol. 81 (1998) 1382-1385
71. Rongen G.A., Oyen W.J.G., Ramakers B.P., Riksen N.P., Boerman O.C., Steinmetz N., and Smits P. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation 111 (2005) 173-178
72. Saito H., Nishimura M., Shinano H., Makita H., Tsujino I., Shibuya E., Sato F., Miyamoto K., and Kawakami Y. Plasma concentration of adenosine during normoxia and moderate hypoxia in humans. Am. J. Respir. Crit. Care Med. 159 (1999) 1014-1018
73. Schrader J., Schutz W., and Bardenheuer H. Role of S-adenosylhomocysteine hydrolase in adenosine metabolism in mammalian heart. Biochem. J. 196 (1981) 65-70
74. 2 adenosine receptors?. Trends Immunol. 26 (2005) 299-304
75. Smits P., Boekema P., De Abreu R., Thien T., and van 't Laar A. Evidence for an antagonism between caffeine and adenosine in the human cardiovascular system. J. Cardiovasc. Pharmacol. 10 (1987) 136-143
76. Smits P., Schouten J., and Thien T. Cardiovascular effects of two xanthines and the relation to adenosine antagonism. Clin. Pharmacol. Ther. 45 (1989) 593-599
77. Smits P., Lenders J.W., and Thien T. Caffeine and theophylline attenuate adenosine-induced vasodilation in humans. Clin. Pharmacol. Ther. 48 (1990) 410-418
78. Smits P., Straatman C., Pijpers E., and Thien T. Dose-dependent inhibition of the hemodynamic response to dipyridamole by caffeine. Clin. Pharmacol. Ther. 50 (1991) 529-537
79. Smits P., Williams S.B., Lipson D.E., Banitt P., Rongen G.A., and Creager M.A. Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans. Circulation 92 (1995) 2135-2141
80. Sollevi A., Ostergren J., Fagrell B., and Hjemdahl P. Theophylline antagonizes cardiovascular responses to dipyridamole in man without affecting increases in plasma adenosine. Acta Physiol. Scand. 121 (1984) 165-171
81. Sylven C., Jonzon B., Fredholm B.B., and Kaijser L. Adenosine injection into the brachial artery produces ischaemia like pain or discomfort in the forearm. Cardiovasc. Res. 22 (1988) 674-678
82. Taddei S., Pedrinelli R., and Salvetti A. Sympathetic nervous system-dependent vasoconstriction in humans. Evidence for mechanistic role of endogenous purine compounds. Circulation 82 (1990) 2061-2067
83. Taddei S., Pedrinelli R., and Salvetti A. Theophylline is an antagonist of adenosine in human forearm arterioles. Am. J. Hypertens. 4 (1991) 256-259
84. Tang Z., Diamond M.A., Chen J.M., Holly T.A., Bonow R.O., Dasgupta A., Hyslop T., Purzycki A., Wagner J., McNamara D.M., Kukulski T., Wos S., Velazquez E.J., Ardlie K., and Feldman A.M. Polymorphisms in adenosine receptor genes are associated with infarct size in patients with ischemic cardiomyopathy. Clin. Pharmacol. Ther. 82 (2007) 435-440
85. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288 (2002) 2015-2022
86. Timmers H.J., Rongen G.A., Karemaker J.M., Wieling W.W., Marres H.A., and Lenders J.W. The role of carotid chemoreceptors in the sympathetic activation by adenosine in humans. Clin. Sci. (Lond.) 106 (2006) 75-82
87. Ueland P.M. Pharmacological and biochemical aspects of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase. Pharmacol. Rev. 34 (1982) 223-253
88. van Ginneken E.E., Rongen G.A., Russel F.G., and Smits P. Diadenosine pentaphosphate vasodilates the forearm vascular bed: inhibition by theophylline and augmentation by dipyridamole. Clin. Pharmacol. Ther. 71 (2002) 448-456
89. Vander Heide R.S., and Reimer K.A. Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc. Res. 31 (1996) 711-718
90. Wilkinson I.B., and Webb D.J. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br. J. Clin. Pharmacol. 52 (2001) 631-646
91. Zernecke A., Bidzhekov K., Ozuyaman B., Fraemohs L., Liehn E.A., Luscher-Firzlaff J.M., Luscher B., Schrader J., and Weber C. CD73/ecto-5 ′-nucleotidase protects against vascular inflammation and neointima formation. Circulation 113 (2006) 2120-2127
92. Zhao Z.Q., Nakanishi K., McGee D.S., Tan P., and Vinten-Johansen J. A1 receptor mediated myocardial infarct size reduction by endogenous adenosine is exerted primarily during ischaemia. Cardiovasc. Res 28 (1994) 270-279
93. Zhao Z.Q., Corvera J.S., Halkos M.E., Kerendi F., Wang N.P., Guyton R.A., and Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am. J. Physiol. Heart. Circ. Physiol. 285 (2003) H579-H588